Amotiv Limited Asset Resilience Ratio
Amotiv Limited asset resilience ratio. Amotiv Limited (AOV) has an Asset Resilience Ratio of 4.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read AOV current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Amotiv Limited (2014–2025)
Asset resilience ratio of Amotiv Limited from 2014 to 2025. This chart shows how Amotiv Limited's Asset Resilience Ratio has changed over time. See AOV cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Amotiv Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Amotiv Limited (AOV) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$5.35 Million | 0.51% |
| Short-term Investments | CA$37.78 Million | 3.61% |
| Total Liquid Assets | CA$43.13 Million | 4.12% |
Asset Resilience Insights
- Limited Liquidity: Amotiv Limited maintains only 4.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Amotiv Limited Industry Peers by Asset Resilience Ratio
Compare Amotiv Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Amotiv Limited Asset Resilience Ratio by Year (2014–2025)
Amotiv Limited asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Amotiv Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.12% | CA$43.13 Million ≈ $31.20 Million |
CA$1.05 Billion ≈ $756.88 Million |
-5.02pp |
| 2024-12-31 | 9.14% | CA$88.13 Million ≈ $63.75 Million |
CA$963.80 Million ≈ $697.20 Million |
-2.67pp |
| 2023-12-31 | 11.82% | CA$111.73 Million ≈ $80.83 Million |
CA$945.49 Million ≈ $683.96 Million |
+0.46pp |
| 2022-12-31 | 11.36% | CA$119.84 Million ≈ $86.69 Million |
CA$1.05 Billion ≈ $763.05 Million |
+2.68pp |
| 2021-12-31 | 8.68% | CA$86.06 Million ≈ $62.26 Million |
CA$991.89 Million ≈ $717.52 Million |
-9.05pp |
| 2020-12-31 | 17.73% | CA$184.33 Million ≈ $133.34 Million |
CA$1.04 Billion ≈ $752.09 Million |
-2.70pp |
| 2019-12-31 | 20.43% | CA$266.69 Million ≈ $192.92 Million |
CA$1.31 Billion ≈ $944.24 Million |
-23.21pp |
| 2018-12-31 | 43.64% | CA$459.03 Million ≈ $332.06 Million |
CA$1.05 Billion ≈ $760.88 Million |
+14.12pp |
| 2017-12-31 | 29.52% | CA$296.93 Million ≈ $214.79 Million |
CA$1.01 Billion ≈ $727.71 Million |
-50.00pp |
| 2016-12-31 | 79.52% | CA$787.84 Million ≈ $569.91 Million |
CA$990.77 Million ≈ $716.71 Million |
+39.87pp |
| 2015-12-31 | 39.65% | CA$257.31 Million ≈ $186.14 Million |
CA$648.99 Million ≈ $469.47 Million |
+10.16pp |
| 2014-12-31 | 29.49% | CA$143.50 Million ≈ $103.81 Million |
CA$486.61 Million ≈ $352.01 Million |
-- |
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more